Coherus Acquires Bevacizumab Rights From Innovent

Deal Also Includes Option To Sell Innovent’s Rituximab Biosimilar

Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.

Coherus
Coherus has acquired rights to an Avastin biosimilar from Innovent • Source: Shutterstock

US biosimilars specialist Coherus BioSciences and China’s Innovent Biologics have struck a deal that gives Coherus US and Canadian rights to a biosimilar version of Avastin (bevacizumab) as well as a “non-exclusive option” to sell Innovent’s biosimilar rival to Rituxan (rituximab) in the US and Canada.

Coherus said it would pay “up to $45m in milestones, including the upfront” for the bevacizumab biosimilar, with milestone payments contingent upon achieving certain regulatory and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business